Hemostats Market

研究執行與發布：MarketsandMarkets　·　發布日期 2025-07-16　·　262 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

完整報告名稱與涵蓋範圍

Hemostats Market by Type (Thrombin, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, General, Cardiovascular), End User (Hospital, Specialty Clinic), Region - Global Forecast to 2030

報告摘要

The global hemostats market is projected to reach 4.0 billion in 2030 from USD 2.9 billion in 2025, at a CAGR of 6.4% during the forecast period.” The escalating demographic of the elderly is driving a significant uptick in the demand for surgical interventions, highlighting the pivotal role of hemostatic agents within modern healthcare. As individuals age, they become more susceptible to a range of chronic conditions necessitating surgical correction to restore or improve functional capacity. This includes procedures such as orthopedic joint replacements and more complex cardiovascular and gastrointestinal surgeries. Aging is associated with physiological changes, including diminished tissue resilience and an elevated propensity for hemorrhage. Consequently, the judicious application of hemostatic agents is critical for optimizing surgical outcomes in geriatric patients. With the global aging population on the rise, the demand for hemostatic products is projected to escalate correspondingly, underscoring their essential contribution to addressing the intricate surgical care requirements of older adults. Nonetheless, the prohibitive costs of advanced hemostatic technologies coupled with limited accessibility in resource-constrained environments may pose challenges to their broader implementation. “Combination hemostats segment accounted for the highest growth rate in the hemostats market, by type, during the study period.” The hemostats market is bifurcated into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats on the basis of type. The market for hemostatic agents is experiencing rapid growth due to the superior efficacy of combination hemostats compared to monotherapy products. These advanced hemostatic agents operate through multiple mechanisms, which enhance their ability to control surgical hemorrhage effectively. Key benefits associated with these combination products include decreased intraoperative blood loss, expedited and reliable hemostasis, reduced convalescence times, and a lower frequency of transfusion requirements. Furthermore, the implementation of combination hemostats has been linked to improved patient outcomes, such as shortened hospital stays and faster recovery trajectories. “Sponge hemostats segment accounted for the highest growth rate in the hemostats market, by formulation, during the forecast period.” The global hemostats market is bifurcated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. The sponge hemostats segment is experiencing the most rapid growth due to an increasing reliance on sponge-based formulations among surgeons and healthcare professionals, attributed to several key advantages. These hemostatic sponges are highly absorbent, user-friendly, and conform well to irregular wound geometries, making them applicable to a wide range of surgical procedures. They facilitate prompt hemostasis, mitigate the risk of postoperative bleeding, and are frequently available in ready-to-use formats, eliminating the need for prior preparation. Furthermore, most sponge hemostats are bioresorbable, which removes the necessity for subsequent removal and minimizes potential complications. Recent advancements in material science have led to the development of sponge hemostats with enhanced biocompatibility and antimicrobial properties, further solidifying their clinical preference. These innovations not only improve the safety profile but also optimize their effectiveness in various surgical contexts. “By application, the orthopedic surgery segment accounted for the largest share of the hemostats market in 2024.” The hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. In 2024, the orthopedic surgery segment dominated the hemostats market, a trend driven by a rising prevalence of lifestyle-related conditions such as arthritis, osteoporosis, and obesity, which often lead to musculoskeletal complications requiring surgical intervention. The demographic shift towards an aging population, which is more susceptible to degenerative bone and joint disorders, also significantly contributes to the increased demand for orthopedic surgical procedures. Moreover, the escalating incidence of sports-related injuries and traumatic fractures necessitates a more substantial number of surgical interventions where precise hemostatic control is crucial. The growing preference for minimally invasive orthopedic techniques, which prioritize effective hemostasis without compromising clinical outcomes, further fuels market demand. Additionally, improved healthcare accessibility in emerging markets, coupled with the availability of advanced hemostatic agents, is facilitating the broader adoption of these products in orthopedic surgical practices. “By region, the Asia Pacific was the fastest-growing region in the hemostats market in 2024.” The global hemostats market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is poised for significant growth in the hemostats market over the forecast period, primarily driven by robust GDP growth and rising disposable incomes in emerging economies. These economic dynamics are facilitating increased healthcare expenditure among broader demographics. The demand for sophisticated surgical products, such as hemostats, is escalating due to a surge in surgical procedures, a higher prevalence of chronic diseases, and the ongoing modernization of healthcare infrastructures. Moreover, the market is propelled by the increasing integration of advanced medical technologies, extending even into rural areas. The rapid expansion of healthcare facilities, particularly hospitals and clinics in China and India, combined with government initiatives to enhance disease management awareness, are critical contributors to this growth. Additionally, the significant uptick in healthcare spending across numerous Asian nations has bolstered the purchasing power of healthcare providers, thereby expediting the adoption of innovative hemostatic agents within the region. The break-up of the profile of primary participants in the hemostats market: • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30% • By Designation: C-level - 27%, Director-level - 18%, and Others - 55% • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4% Prominent players in the hemostats market include Johnson & Johnson Services, Inc. (US), Baxter (US), Pfizer Inc. (US), B. Braun SE (Germany), BD (US), Teleflex Incorporated (US), Medtronic (Ireland), Hemostasis, LLC (US), Stryker ((US), Integra LifeSciences Corporation (US), Advanced Medical Solutions Group plc (UK), Samyang Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL (Germany), Dilon Technologies (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Development GmbH (Germany), Unilene (Peru), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), CELOX Medical Ltd. (UK), and Altaylar Medical (Turkey). Research Coverage The report analyzes the hemostats market, estimating the market size and potential for future growth across various segments, including end users, regions, applications, type, and formulation. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product offerings, recent developments, and key market strategies. Reasons to Buy the Report The report provides valuable insights for market leaders and new entrants in the hemostats industry, offering approximate revenue figures for the overall market and its subsegments. It assists stakeholders in understanding the competitive landscape, enabling them to position their businesses better and develop effective go-to-market strategies. Additionally, the report highlights key market drivers, restraints, challenges, and opportunities, helping stakeholders gauge the current state of the market. This report provides insights into the following pointers:  Analysis of key drivers (growing volume of surgical procedures performed, rising focus on R&D, and increasing emphasis on effective blood loss management in patients during surgeries), restraints (side effects and allergic reactions associated with hemostats), opportunities (increasing growth opportunities in emerging economies), and challenges (stringent regulatory framework, dearth of skilled personnel for effective use of hemostats, and high cost of hemostats) influencing the growth of the hemostats market. • Market Penetration: It provides detailed information on the product portfolios that major players in the global hemostats market offer. The report covers various segments: end user, region, application, type, and formulation. • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global hemostats market. • Market Development: Comprehensive information about lucrative markets – the report analyses the hemostats market across varied regions. • Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global hemostats market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global hemostats market.

授權報價

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

目錄 Table of Contents

1 INTRODUCTION 23 1.1 STUDY OBJECTIVES 23 1.2 MARKET DEFINITION 23 1.3 MARKET SCOPE 24 1.3.1 INCLUSIONS AND EXCLUSIONS 24 1.3.2 MARKETS COVERED 25 1.3.3 YEARS CONSIDERED 26 1.4 CURRENCY CONSIDERED 26 1.5 UNIT CONSIDERED 26 1.6 STAKEHOLDERS 26 1.7 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 28 2.1 RESEARCH DATA 28 2.1.1 SECONDARY DATA 29 2.1.1.1 Key data from secondary sources 30 2.1.2 PRIMARY DATA 30 2.1.2.1 Key data from primary sources 31 2.1.2.2 Key industry insights 32 2.2 MARKET SIZE ESTIMATION 33 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 38 2.4 MARKET SHARE ESTIMATION 39 2.5 RESEARCH ASSUMPTIONS 39 2.6 RESEARCH LIMITATIONS 39 2.6.1 SCOPE-RELATED LIMITATIONS 39 2.6.2 METHODOLOGY-RELATED LIMITATIONS 39 2.7 RISK ASSESSMENT 40 3 EXECUTIVE SUMMARY 41 4 PREMIUM INSIGHTS 45 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN HEMOSTATS MARKET 45 4.2 ASIA PACIFIC HEMOSTATS MARKET, BY END USER AND COUNTRY 46 4.3 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47 4.4 REGIONAL MIX: HEMOSTATS MARKET (2023–2030) 47 4.5 HEMOSTATS MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2025 VS. 2030 (USD MILLION) 48 5 MARKET OVERVIEW 49 5.1 INTRODUCTION 49 5.2 MARKET DYNAMICS 49 5.2.1 DRIVERS 50 5.2.1.1 Growing volume of surgical procedures performed 50 5.2.1.2 Increasing focus on R&D 52 5.2.1.3 Rising focus on effective blood loss management in patients during surgeries 53 5.2.2 RESTRAINTS 53 5.2.2.1 Side effects and allergic reactions associated with hemostats 53 5.2.3 OPPORTUNITIES 54 5.2.3.1 High growth potential in emerging economies 54 5.2.3.2 Growing number of hospitals 55 5.2.4 CHALLENGES 56 5.2.4.1 Stringent regulatory requirements for hemostat products 56 5.2.4.2 Lack of skilled personnel for effective use of hemostats 56 5.2.4.3 High cost of hemostats 56 5.3 INDUSTRY TRENDS 57 5.3.1 INCREASED POPULARITY OF COMBINATION HEMOSTATS 57 5.3.2 CONSOLIDATION OF HOSPITALS 57 5.4 TECHNOLOGY ANALYSIS 57 5.4.1 KEY TECHNOLOGIES 57 5.4.1.1 Passive hemostats 57 5.4.1.2 Chitosan-based hemostats 58 5.4.2 COMPLEMENTARY TECHNOLOGIES 58 5.4.2.1 Surgical adhesives 58 5.4.3 ADJACENT TECHNOLOGIES 58 5.4.3.1 Drug-eluting sutures for local therapeutic delivery 58 5.4.3.2 Barbed sutures 58 5.5 PRICING ANALYSIS 59 5.5.1 AVERAGE SELLING PRICE TREND, BY HEMOSTAT 59 5.5.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION, 2022–2024 (USD) 59 5.6 ECOSYSTEM/MARKET MAP 60 5.7 REIMBURSEMENT SCENARIO 61 5.8 VALUE CHAIN ANALYSIS 61 5.9 PORTER’S FIVE FORCES ANALYSIS 63 5.9.1 THREAT OF NEW ENTRANTS 64 5.9.2 THREAT OF SUBSTITUTES 64 5.9.3 BARGAINING POWER OF SUPPLIERS 64 5.9.4 BARGAINING POWER OF BUYERS 64 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 65 5.10 SUPPLY CHAIN ANALYSIS 65 5.11 TRADE ANALYSIS 66 5.11.1 IMPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020–2024 66 5.11.2 EXPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020–2024 67 5.12 REGULATORY LANDSCAPE 67 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67 5.12.2 REGULATORY FRAMEWORK 70 5.12.2.1 North America 70 5.12.2.1.1 US 70 5.12.2.1.2 Canada 71 5.12.2.2 Europe 72 5.12.2.3 Asia Pacific 72 5.12.2.3.1 Japan 72 5.12.2.3.2 China 73 5.12.2.3.3 India 74 5.13 PATENT ANALYSIS 74 5.13.1 PATENT PUBLICATION TRENDS FOR HEMOSTATS MARKET 74 5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN HEMOSTATS MARKET 74 5.14 KEY CONFERENCES & EVENTS 77 5.15 KEY STAKEHOLDERS & BUYING CRITERIA 78 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 78 5.15.2 KEY BUYING CRITERIA 78 5.16 ADJACENT MARKET ANALYSIS 79 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79 5.18 UNMET NEEDS/END-USER EXPECTATIONS 80 5.19 IMPACT OF ARTIFICIAL INTELLIGENCE (AI) ON HEMOSTATS MARKET 81 5.20 CASE STUDY ANALYSIS 82 5.20.1 EGYPT’S INCURA LEVERAGES MACHINE LEARNING TO REINVENT TRAUMA HEMOSTASIS 82 5.20.2 SOLE-SUPPLIER TRANSITION FOR HEMOSTATIC AGENTS AT OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 83 5.21 INVESTMENT AND FUNDING SCENARIO 83 5.22 IMPACT OF US TARIFF – HEMOSTATS MARKET 84 5.22.1 INTRODUCTION 84 5.22.2 KEY TARIFF RATES 84 5.22.3 PRICE IMPACT ANALYSIS 85 5.22.4 IMPACT ON REGION 86 5.22.4.1 US 86 5.22.4.2 Europe 86 5.22.4.3 Asia Pacific 86 5.22.5 IMPACT ON END-USE INDUSTRIES 86 6 HEMOSTATS MARKET, BY TYPE 87 6.1 INTRODUCTION 88 6.2 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS 88 6.2.1 HIGH BIOCOMPATIBILITY TO DRIVE ITS ADOPTION 88 6.3 THROMBIN-BASED HEMOSTATS 91 6.3.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH 91 6.4 COMBINATION HEMOSTATS 93 6.4.1 ADVANCEMENTS IN COMBINATION MATERIALS TO DRIVE MARKET 93 6.5 GELATIN-BASED HEMOSTATS 94 6.5.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND 94 6.6 COLLAGEN-BASED HEMOSTATS 96 6.6.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS 96 6.7 OTHER HEMOSTATS 98 7 HEMOSTATS MARKET, BY FORMULATION 99 7.1 INTRODUCTION 100 7.2 MATRIX & GEL HEMOSTATS 100 7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET 100 7.3 SHEET & PAD HEMOSTATS 102 7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION 102 7.4 SPONGE HEMOSTATS 103 7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO DRIVE DEMAND 103 7.5 POWDER HEMOSTATS 105 7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO DRIVE DEMAND 105 8 HEMOSTATS MARKET, BY APPLICATION 107 8.1 INTRODUCTION 108 8.2 ORTHOPEDIC SURGERY 108 8.2.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH 108 8.3 GENERAL SURGERY 111 8.3.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH 111 8.4 NEUROLOGICAL SURGERY 112 8.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET 112 8.5 CARDIOVASCULAR SURGERY 113 8.5.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS 113 8.6 RECONSTRUCTIVE SURGERY 115 8.6.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH 115 8.7 GYNECOLOGICAL SURGERY 116 8.7.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH 116 8.8 OTHER SURGICAL APPLICATIONS 118 9 HEMOSTATS MARKET, BY END USER 120 9.1 INTRODUCTION 121 9.2 HOSPITALS 121 9.2.1 GROWING ADOPTION OF MINIMALLY INVASIVE SURGERIES TO BOOST ADOPTION OF HEMOSTATS 121 9.3 SPECIALTY CLINICS 122 9.3.1 EXPANDING SPECIALTY CLINICS TO PROMOTE MARKET GROWTH 122 9.4 OTHERS 124 10 HEMOSTATS MARKET, BY REGION 125 10.1 INTRODUCTION 126 10.2 NORTH AMERICA 127 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 128 10.2.2 US 130 10.2.2.1 Strong healthcare infrastructure to support uptake of hemostats 130 10.2.3 CANADA 133 10.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand 133 10.3 EUROPE 136 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 136 10.3.2 GERMANY 140 10.3.2.1 High healthcare expenditure in Germany to drive market 140 10.3.3 UK 142 10.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market 142 10.3.4 FRANCE 145 10.3.4.1 Presence of well-established healthcare system to drive market growth 145 10.3.5 ITALY 148 10.3.5.1 Increasing volume of surgeries to drive demand for hemostats 148 10.3.6 SPAIN 151 10.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market 151 10.3.7 REST OF EUROPE 153 10.4 ASIA PACIFIC 155 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 156 10.4.2 CHINA 158 10.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth 158 10.4.3 JAPAN 161 10.4.3.1 Strong healthcare system and rising geriatric population to support market growth 161 10.4.4 INDIA 163 10.4.4.1 Rising healthcare awareness and favorable government support to drive market 163 10.4.5 AUSTRALIA 165 10.4.5.1 Well-established healthcare infrastructure to drive adoption of hemostats 165 10.4.6 SOUTH KOREA 167 10.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats 167 10.4.7 REST OF ASIA PACIFIC 169 10.5 LATIN AMERICA 171 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 171 10.5.2 BRAZIL 173 10.5.2.1 Brazil to dominate Latin American market for hemostats 173 10.5.3 MEXICO 175 10.5.3.1 Low-cost surgeries to drive medical tourism in Mexico 175 10.5.4 REST OF LATIN AMERICA 177 10.6 MIDDLE EAST & AFRICA 179 10.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 179 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 180 10.6.3 GCC COUNTRIES 182 10.6.4 REST OF MIDDLE EAST & AFRICA 184 11 COMPETITIVE LANDSCAPE 187 11.1 INTRODUCTION 187 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 187 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET 188 11.3 REVENUE SHARE ANALYSIS 189 11.4 MARKET SHARE ANALYSIS 189 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 191 11.5.1 STARS 191 11.5.2 EMERGING LEADERS 191 11.5.3 PERVASIVE PLAYERS 191 11.5.4 PARTICIPANTS 191 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 193 11.5.5.1 Company footprint 193 11.5.5.2 Region footprint 194 11.5.5.3 Type footprint 195 11.5.5.4 Formulation footprint 196 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 197 11.6.1 PROGRESSIVE COMPANIES 197 11.6.2 RESPONSIVE COMPANIES 197 11.6.3 DYNAMIC COMPANIES 197 11.6.4 STARTING BLOCKS 197 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 199 11.6.5.1 Detailed list of key startups/SMEs 199 11.6.5.2 Competitive benchmarking of key startups/SMEs 199 11.7 VALUATION & FINANCIAL METRICS 200 11.7.1 FINANCIAL METRICS 200 11.7.2 COMPANY VALUATION 200 11.8 BRAND/PRODUCT COMPARISON 201 11.9 R&D EXPENDITURE OF KEY PLAYERS 202 11.10 COMPETITIVE SCENARIO 202 11.10.1 PRODUCT LAUNCHES AND APPROVALS 202 11.10.2 DEALS 203 11.10.3 EXPANSIONS 204 11.10.4 OTHER DEVELOPMENTS 205 12 COMPANY PROFILES 206 12.1 KEY PLAYERS 206 12.1.1 JOHNSON & JOHNSON SERVICES, INC. 206 12.1.1.1 Business overview 206 12.1.1.2 Products offered 207 12.1.1.3 Recent developments 208 12.1.1.3.1 Product approvals & launches 208 12.1.1.3.2 Deals 208 12.1.1.3.3 Other developments 208 12.1.1.4 MnM view 209 12.1.1.4.1 Right to win 209 12.1.1.4.2 Strategic choices 209 12.1.1.4.3 Weaknesses and competitive threats 209 12.1.2 BAXTER 210 12.1.2.1 Business overview 210 12.1.2.2 Products offered 211 12.1.2.3 Recent developments 212 12.1.2.3.1 Product approvals & launches 212 12.1.2.3.2 Other developments 212 12.1.2.4 MnM view 213 12.1.2.4.1 Right to win 213 12.1.2.4.2 Strategic choices 213 12.1.2.4.3 Weaknesses and competitive threats 213 12.1.3 PFIZER INC. 214 12.1.3.1 Business overview 214 12.1.3.2 Products offered 216 12.1.3.3 Recent developments 216 12.1.3.4 MnM view 217 12.1.3.4.1 Right to win 217 12.1.3.4.2 Strategic choices 217 12.1.3.4.3 Weaknesses and competitive threats 217 12.1.4 B. BRAUN SE 218 12.1.4.1 Business overview 218 12.1.4.2 Products offered 220 12.1.4.3 Recent developments 220 12.1.4.4 MnM view 221 12.1.4.4.1 Right to win 221 12.1.4.4.2 Strategic choices 221 12.1.4.4.3 Weaknesses and competitive threats 221 12.1.5 BECTON, DICKINSON AND COMPANY (BD) 222 12.1.5.1 Business overview 222 12.1.5.2 Products offered 223 12.1.5.3 Recent developments 224 12.1.5.3.1 Other developments 224 12.1.5.4 MnM view 224 12.1.5.4.1 Right to win 224 12.1.5.4.2 Strategic choices 224 12.1.5.4.3 Weaknesses and competitive threats 224 12.1.6 TELEFLEX INCORPORATED 225 12.1.6.1 Business overview 225 12.1.6.2 Products offered 226 12.1.6.3 Recent developments 227 12.1.6.3.1 Product approvals & launches 227 12.1.6.3.2 Deals 228 12.1.6.3.3 Other developments 228 12.1.7 MEDTRONIC PLC 229 12.1.7.1 Business overview 229 12.1.7.2 Products offered 230 12.1.7.3 Recent developments 231 12.1.7.3.1 Product approvals & launches 231 12.1.7.3.2 Expansions 231 12.1.8 HEMOSTASIS, LLC 232 12.1.8.1 Business overview 232 12.1.8.2 Products offered 232 12.1.8.3 Recent developments 233 12.1.8.3.1 Deals 233 12.1.9 STRYKER 234 12.1.9.1 Business overview 234 12.1.9.2 Products offered 235 12.1.9.3 Recent developments 236 12.1.9.3.1 Expansions 236 12.1.10 INTEGRA LIFESCIENCES 237 12.1.10.1 Business overview 237 12.1.10.2 Products offered 238 12.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC 239 12.1.11.1 Business overview 239 12.1.11.2 Products offered 241 12.1.11.3 Recent developments 241 12.1.11.3.1 Deals 241 12.1.12 SAMYANG CORPORATION 242 12.1.12.1 Business overview 242 12.1.12.2 Products offered 243 12.2 OTHER PLAYERS 244 12.2.1 MARINE POLYMER TECHNOLOGIES, INC. 244 12.2.2 GELITA MEDICAL 245 12.2.3 DILON TECHNOLOGIES 246 12.2.4 BETATECH MEDICAL 247 12.2.5 MERIL LIFE SCIENCES PVT. LTD. 248 12.2.6 BIOCER DEVELOPMENT GMBH 249 12.2.7 UNILENE 249 12.2.8 KATSAN MEDICAL DEVICES 250 12.2.9 TRICOL BIOMEDICAL 251 12.2.10 3-D MATRIX MEDICAL TECHNOLOGY 252 12.2.11 HEMOSTAT MEDICAL GMBH 252 12.2.12 CELOX MEDICAL LTD. 253 12.2.13 ALTAYLAR MEDICAL 253 13 APPENDIX 254 13.1 DISCUSSION GUIDE 254 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 258 13.3 CUSTOMIZATION OPTIONS 260 13.4 RELATED REPORT 260 13.5 AUTHOR DETAILS 261

圖表清單 List of Tables & Figures

TABLE 1 STANDARD CURRENCY CONVERSION RATES 26 TABLE 2 RESEARCH ASSUMPTIONS 39 TABLE 3 RISK ASSESSMENT 40 TABLE 4 GERIATRIC POPULATION, BY REGION, 2016 VS. 2023 50 TABLE 5 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021 51 TABLE 6 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021 52 TABLE 7 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD) 55 TABLE 8 INDICATIVE PRICING FOR HEMOSTATS 59 TABLE 9 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION, 2022–2024 (USD) 59 TABLE 10 ROLE IN ECOSYSTEM: HEMOSTATS MARKET 60 TABLE 11 HEMOSTATS MARKET: PORTER’S FIVE FORCES ANALYSIS 63 TABLE 12 IMPORT DATA FOR HEMOSTATS (HS CODE: 300610), BY COUNTRY, 2020–2024 (USD THOUSAND) 66 TABLE 13 EXPORT DATA FOR HEMOSTATS (HS CODE: 300610), BY COUNTRY, 2020–2024 (USD THOUSAND) 67 TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67 TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68 TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69 TABLE 19 CLASSIFICATION OF MEDICAL DEVICES BY US FDA 70 TABLE 20 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN 73 TABLE 21 NMPA MEDICAL DEVICES CLASSIFICATION 73 TABLE 22 LIST OF MAJOR PATENTS IN HEMOSTATS MARKET 2022–2024 76 TABLE 23 HEMOSTATS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, 2025–2026 77 TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF END USERS 78 TABLE 25 KEY BUYING CRITERIA FOR END USERS 79 TABLE 26 HEMOSTATS MARKET: UNMET NEEDS 80 TABLE 27 HEMOSTATS MARKET: END-USER EXPECTATIONS 81 TABLE 28 US-ADJUSTED RECIPROCAL TARIFF RATES 84 TABLE 29 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR HEMOSTATS 85 TABLE 30 HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 88 TABLE 31 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET 89 TABLE 32 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 90 TABLE 33 MAJOR PRODUCTS IN THROMBIN-BASED HEMOSTATS MARKET 91 TABLE 34 THROMBIN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 92 TABLE 35 MAJOR PRODUCTS IN COMBINATION HEMOSTATS MARKET 93 TABLE 36 COMBINATION HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 37 MAJOR PRODUCTS IN GELATIN-BASED HEMOSTATS MARKET 95 TABLE 38 GELATIN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 95 TABLE 39 MAJOR PRODUCTS IN COLLAGEN-BASED HEMOSTATS MARKET 96 TABLE 40 COLLAGEN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 41 OTHER HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 42 HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 100 TABLE 43 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 44 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 101 TABLE 45 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 46 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 103 TABLE 47 SPONGE HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 48 SPONGE HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 104 TABLE 49 POWDER HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 50 POWDER HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 106 TABLE 51 HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 108 TABLE 52 NUMBER OF KNEE & HIP REPLACEMENTS, 2021 109 TABLE 53 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 54 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021 111 TABLE 55 HEMOSTATS MARKET FOR GENERAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 56 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 57 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 58 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 59 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 60 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 61 HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 121 TABLE 62 HEMOSTATS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 63 HEMOSTATS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 64 HEMOSTATS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 65 HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 129 TABLE 68 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 129 TABLE 69 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 130 TABLE 70 NORTH AMERICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 130 TABLE 71 US: KEY MACROINDICATORS 131 TABLE 72 US: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 132 TABLE 73 US: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 132 TABLE 74 US: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 133 TABLE 75 US: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 133 TABLE 76 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021 134 TABLE 77 CANADA: KEY MACROINDICATORS 134 TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 79 CANADA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 135 TABLE 80 CANADA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 135 TABLE 81 CANADA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 135 TABLE 82 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 83 EUROPE: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 138 TABLE 84 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 139 TABLE 85 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 139 TABLE 86 EUROPE: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 139 TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021 140 TABLE 88 GERMANY: KEY MACROINDICATORS 141 TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 90 GERMANY: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 141 TABLE 91 GERMANY: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 142 TABLE 92 GERMANY: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 142 TABLE 93 SURGICAL PROCEDURES PERFORMED IN UK, 2021 143 TABLE 94 UK: KEY MACROINDICATORS 143 TABLE 95 UK: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 96 UK: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 144 TABLE 97 UK: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 145 TABLE 98 UK: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 145 TABLE 99 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021 146 TABLE 100 FRANCE: KEY MACROINDICATORS 146 TABLE 101 FRANCE: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 102 FRANCE: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 147 TABLE 103 FRANCE: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 148 TABLE 104 FRANCE: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 148 TABLE 105 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021 149 TABLE 106 ITALY: KEY MACROINDICATORS 149 TABLE 107 ITALY: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 108 ITALY: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 150 TABLE 109 ITALY: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 150 TABLE 110 ITALY: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 150 TABLE 111 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021 151 TABLE 112 SPAIN: KEY MACROINDICATORS 152 TABLE 113 SPAIN: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 114 SPAIN: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 152 TABLE 115 SPAIN: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 153 TABLE 116 SPAIN: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 153 TABLE 117 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY 154 TABLE 118 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 119 REST OF EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 154 TABLE 120 REST OF EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 155 TABLE 121 REST OF EUROPE: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 155 TABLE 122 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 123 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 124 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 157 TABLE 125 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 158 TABLE 126 ASIA PACIFIC: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 128 CHINA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 160 TABLE 129 CHINA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 160 TABLE 130 CHINA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 160 TABLE 131 JAPAN: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 132 JAPAN: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 162 TABLE 133 JAPAN: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 162 TABLE 134 JAPAN: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 162 TABLE 135 INDIA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 163 TABLE 136 INDIA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 164 TABLE 137 INDIA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 164 TABLE 138 INDIA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 164 TABLE 139 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 140 AUSTRALIA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 166 TABLE 141 AUSTRALIA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 166 TABLE 142 AUSTRALIA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 166 TABLE 143 SURGICAL PROCEDURES IN SOUTH KOREA, 2021 167 TABLE 144 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 145 SOUTH KOREA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 168 TABLE 146 SOUTH KOREA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 168 TABLE 147 SOUTH KOREA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 148 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 149 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 170 TABLE 150 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 170 TABLE 151 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 170 TABLE 152 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 153 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 154 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 172 TABLE 155 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 173 TABLE 156 LATIN AMERICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 173 TABLE 157 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 158 BRAZIL: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 174 TABLE 159 BRAZIL: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 175 TABLE 160 BRAZIL: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 175 TABLE 161 MEXICO: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 162 MEXICO: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 176 TABLE 163 MEXICO: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 177 TABLE 164 MEXICO: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 177 TABLE 165 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 166 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 178 TABLE 167 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 179 TABLE 168 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 179 TABLE 169 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 170 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 171 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 181 TABLE 172 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 182 TABLE 173 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 182 TABLE 174 GCC COUNTRIES: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 175 GCC COUNTRIES: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 183 TABLE 176 GCC COUNTRIES: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 184 TABLE 177 GCC COUNTRIES: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 184 TABLE 178 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 179 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION) 185 TABLE 180 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 186 TABLE 181 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 182 STRATEGIES ADOPTED BY KEY PLAYERS IN HEMOSTATS MARKET, JANUARY 2022–MAY 2025 188 TABLE 183 HEMOSTATS MARKET: DEGREE OF COMPETITION 190 TABLE 184 HEMOSTATS MARKET: REGION FOOTPRINT 194 TABLE 185 HEMOSTATS MARKET: TYPE FOOTPRINT 195 TABLE 186 HEMOSTATS MARKET: FORMULATION FOOTPRINT 196 TABLE 187 HEMOSTATS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 199 TABLE 188 HEMOSTATS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 199 TABLE 189 HEMOSTATS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MAY 2025 202 TABLE 190 HEMOSTATS MARKET: DEALS, JANUARY 2022–MAY 2025 203 TABLE 191 HEMOSTATS MARKET: EXPANSIONS, JANUARY 2022–MAY 2025 204 TABLE 192 HEMOSTATS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 205 TABLE 193 JOHNSON & JOHNSON: COMPANY OVERVIEW 206 TABLE 194 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 207 TABLE 195 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS LAUNCHES, JANUARY 2022–MAY 2025 208 TABLE 196 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022–MAY 2025 208 TABLE 197 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 208 TABLE 198 BAXTER: COMPANY OVERVIEW 210 TABLE 199 BAXTER: PRODUCTS OFFERED 211 TABLE 200 BAXTER: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022–MAY 2025 212 TABLE 201 BAXTER: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 212 TABLE 202 PFIZER INC.: COMPANY OVERVIEW 214 TABLE 203 PFIZER INC.: PRODUCTS OFFERED 216 TABLE 204 B. BRAUN SE: COMPANY OVERVIEW 218 TABLE 205 B. BRAUN SE: PRODUCTS OFFERED 220 TABLE 206 BD: COMPANY OVERVIEW 222 TABLE 207 BD: PRODUCTS OFFERED 223 TABLE 208 BD: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 224 TABLE 209 TELEFLEX INCORPORATED: COMPANY OVERVIEW 225 TABLE 210 TELEFLEX INCORPORATED: PRODUCTS OFFERED 226 TABLE 211 TELEFLEX INCORPORATED: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022–MAY 2025 227 TABLE 212 TELEFLEX INCORPORATED: DEALS, JANUARY 2022–MAY 2025 228 TABLE 213 TELEFLEX INCORPORATED: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025 228 TABLE 214 MEDTRONIC: COMPANY OVERVIEW 229 TABLE 215 MEDTRONIC: PRODUCTS OFFERED 230 TABLE 216 MEDTRONIC: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022–MAY 2025 231 TABLE 217 MEDTRONIC: EXPANSIONS, JANUARY 2022–MAY 2025 231 TABLE 218 HEMOSTASIS, LLC: COMPANY OVERVIEW 232 TABLE 219 HEMOSTASIS, LLC: PRODUCTS OFFERED 232 TABLE 220 HEMOSTASIS, LLC: DEALS, JANUARY 2022–MAY 2025 233 TABLE 221 STRYKER: COMPANY OVERVIEW 234 TABLE 222 STRYKER: PRODUCTS OFFERED 235 TABLE 223 STRYKER: EXPANSIONS, JANUARY 2022–MAY 2025 236 TABLE 224 INTEGRA LIFESCIENCES: COMPANY OVERVIEW 237 TABLE 225 INTEGRA LIFESCIENCES: PRODUCTS OFFERED 238 TABLE 226 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY OVERVIEW 239 TABLE 227 ADVANCED MEDICAL SOLUTIONS GROUP PLC: PRODUCTS OFFERED 241 TABLE 228 ADVANCED MEDICAL SOLUTIONS GROUP PLC: DEALS, JANUARY 2022–MAY 2025 241 TABLE 229 SAMYANG CORPORATION: COMPANY OVERVIEW 242 TABLE 230 SAMYANG CORPORATION: PRODUCTS OFFERED 243 FIGURE 1 RESEARCH DESIGN 28 FIGURE 2 PRIMARY SOURCES 30 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 32 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 33 FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2024) 34 FIGURE 6 REVENUE SHARE ANALYSIS FOR JHONSON & JOHNSON SERVICES, INC. (US) (2024) 34 FIGURE 7 HEMOSTATS MARKET: SUPPLY SIDE ANALYSIS (2024) 35 FIGURE 8 TOP-DOWN APPROACH 36 FIGURE 9 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS (2025–2030) 37 FIGURE 10 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 37 FIGURE 11 DATA TRIANGULATION METHODOLOGY 38 FIGURE 12 HEMOSTATS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 41 FIGURE 13 HEMOSTATS MARKET, BY FORMULATION, 2025 VS. 2030 (USD MILLION) 42 FIGURE 14 HEMOSTATS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 42 FIGURE 15 HEMOSTATS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 43 FIGURE 16 HEMOSTATS MARKET: REGIONAL SNAPSHOT 44 FIGURE 17 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH 45 FIGURE 18 CHINA TO ACCOUNT FOR LARGEST SHARE IN ASIA PACIFIC 46 FIGURE 19 INDIA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 47 FIGURE 20 NORTH AMERICA TO DOMINATE HEMOSTATS MARKET DURING FORECAST PERIOD 47 FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGH GROWTH DURING FORECAST PERIOD 48 FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN HEMOSTATS MARKET 49 FIGURE 23 HEMOSTATS MARKET: ROLE IN ECOSYSTEM, 2024 60 FIGURE 24 HEMOSTATS MARKET: VALUE CHAIN ANALYSIS 62 FIGURE 25 PORTER’S FIVE FORCES ANALYSIS: HEMOSTATS MARKET 63 FIGURE 26 HEMOSTATS MARKET: SUPPLY CHAIN ANALYSIS 66 FIGURE 27 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES 71 FIGURE 28 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA 71 FIGURE 29 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS 72 FIGURE 30 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR HEMOSTATS MARKET (JANUARY 2014–DECEMBER 2024) 75 FIGURE 31 TOP PATENT APPLICANT COUNTRIES FOR HEMOSTATS MARKET (JANUARY 2014–DECEMBER 2024) 76 FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF END USERS 78 FIGURE 33 KEY BUYING CRITERIA FOR END USERS 78 FIGURE 34 HEMOSTATS MARKET: ADJACENT MARKETS 79 FIGURE 35 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80 FIGURE 36 INVESTMENT/VENTURE CAPITAL SCENARIO IN HEMOSTATS MARKET, 2022–2024 83 FIGURE 37 HEMOSTATS MARKET: GEOGRAPHIC SNAPSHOT (2025–2030) 126 FIGURE 38 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT 128 FIGURE 39 EUROPE: HEMOSTATS MARKET SNAPSHOT 137 FIGURE 40 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT 156 FIGURE 41 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2022–2024 189 FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HEMOSTATS MARKET (2024) 189 FIGURE 43 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 192 FIGURE 44 HEMOSTATS MARKET: COMPANY FOOTPRINT 193 FIGURE 45 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 198 FIGURE 46 EV/EBITDA OF KEY VENDORS 200 FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 200 FIGURE 48 HEMOSTATS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 201 FIGURE 49 R&D EXPENDITURE OF KEY PLAYERS IN HEMOSTATS MARKET, 2022–2024 202 FIGURE 50 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024) 207 FIGURE 51 BAXTER: COMPANY SNAPSHOT (2024) 211 FIGURE 52 PFIZER INC.: COMPANY SNAPSHOT (2024) 215 FIGURE 53 B. BRAUN SE: COMPANY SNAPSHOT: (2024) 219 FIGURE 54 BD: COMPANY SNAPSHOT (2024) 223 FIGURE 55 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2024) 226 FIGURE 56 MEDTRONIC: COMPANY SNAPSHOT (2024) 230 FIGURE 57 STRYKER: COMPANY SNAPSHOT (2024) 235 FIGURE 58 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2024) 238 FIGURE 59 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2024) 240 FIGURE 60 SAMYANG CORPORATION: COMPANY SNAPSHOT (2024) 242

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們